University of Parma

Running trials

• Recruiting

  Feasibility of a Multi-omics Platform for Hematological Malignancies

  NCT07445438· Azienda Ospedaliero-Universitaria di Parma· Source

• Recruiting

  Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

  NCT06823466· University of L'Aquila· Source

• Recruiting

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source

• Active, not recruiting

  Obsessive-Compulsive Disorder: Insight, Trauma, and Links to Schizophrenia Spectrum Disorders

  NCT07092826· Matteo Tonna· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

  NCT07445984· Azienda Ospedaliero-Universitaria di Parma· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Myeloproliferative neoplasms2 recruiting
• Stroke2 recruiting
• Atrial fibrillation1 recruiting
• Multiple myeloma1 recruiting
• Neuroblastoma1 recruiting

Closed trials

• Completed

  MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management

  NCT07757386· Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS· Source

• Completed

  Effect of Pulmonary Rehabilitation and Physical Activity on COVID-19 Long-Term Symptoms (PuReCOVID)

  NCT07046442· University of Parma· Source

• Completed

  Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

  NCT02719574· Phase 1/2· Forma Therapeutics, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer33 works · 0 trials
• Migraine16 works · 0 trials
• Idiopathic pulmonary fibrosis14 works · 0 trials
• Lewy body dementia6 works · 0 trials
• Osteonecrosis (avascular necrosis)6 works · 0 trials
• Spinal muscular atrophy5 works · 0 trials
• Lichen planus5 works · 0 trials
• Chronic spontaneous urticaria3 works · 0 trials